Gilead Sciences, Inc. (GILD) Stake Increased by Dai Ichi Life Insurance Company Ltd

Dai Ichi Life Insurance Company Ltd grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 160,025 shares of the biopharmaceutical company’s stock after acquiring an additional 11,299 shares during the quarter. Dai Ichi Life Insurance Company Ltd’s holdings in Gilead Sciences were worth $11,327,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Weatherstone Capital Management increased its stake in Gilead Sciences by 22.1% during the 2nd quarter. Weatherstone Capital Management now owns 5,474 shares of the biopharmaceutical company’s stock worth $387,000 after purchasing an additional 989 shares in the last quarter. Vantage Investment Advisors LLC increased its stake in Gilead Sciences by 6.4% during the 2nd quarter. Vantage Investment Advisors LLC now owns 3,937 shares of the biopharmaceutical company’s stock worth $264,000 after purchasing an additional 236 shares in the last quarter. Johnson Financial Group Inc. increased its stake in Gilead Sciences by 34.1% during the 2nd quarter. Johnson Financial Group Inc. now owns 46,280 shares of the biopharmaceutical company’s stock worth $3,276,000 after purchasing an additional 11,768 shares in the last quarter. Skba Capital Management LLC increased its stake in Gilead Sciences by 33.7% during the 2nd quarter. Skba Capital Management LLC now owns 142,500 shares of the biopharmaceutical company’s stock worth $10,086,000 after purchasing an additional 35,900 shares in the last quarter. Finally, Aberdeen Asset Management PLC UK increased its stake in Gilead Sciences by 9.3% during the 2nd quarter. Aberdeen Asset Management PLC UK now owns 2,057,324 shares of the biopharmaceutical company’s stock worth $145,617,000 after purchasing an additional 175,102 shares in the last quarter. 74.62% of the stock is owned by institutional investors.

A number of analysts recently issued reports on GILD shares. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 2nd. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 target price for the company in a research note on Friday, July 28th. Redburn Partners started coverage on Gilead Sciences in a research note on Wednesday, July 26th. They set a “buy” rating for the company. Finally, Deutsche Bank AG reissued a “buy” rating and set a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $84.87.

In other Gilead Sciences news, EVP Gregg H. Alton sold 50,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now owns 113,237 shares in the company, valued at $8,945,723. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold 666,819 shares of company stock worth $52,303,086 in the last 90 days. 1.30% of the stock is owned by company insiders.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.44 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The company has a market capitalization of $94,560.00, a price-to-earnings ratio of 7.43, a P/E/G ratio of -1.19 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the business earned $2.75 earnings per share. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.87%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.66%.

COPYRIGHT VIOLATION WARNING: This news story was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://ledgergazette.com/2017/11/18/gilead-sciences-inc-gild-stake-increased-by-dai-ichi-life-insurance-company-ltd.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply